Effect of Boswellia in psoriasis

Phase 3

Recruiting

• Conditions: Plaque Psoriasis.; Plaque psoriasis

• Registration Number: IRCT20180804040694N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

Diagnosed with clinical of mild to moderate Plaque Psoriasis
Age between 18-70 years old
PASI score <12
Involvement of body surface area <10%
Written informed consent

Exclusion Criteria

Gguttate, erythrodernic, psoriatic arthritis or pustular psoriasis at the time of screening; psoriasis vulgaris patients with face involvement only;
Known allergic or hypersensitive reactions to cream components;
Using medications that could trigger psoriasis like beta blockers, antimalarials, terbinafine, calcium channel blockers, interleukins and lithium;
Previous treatment with systemic corticosteroids, biologic and immunosuppression drugs or psoralen ultraviolet A therapy within the previous four weeks;
Previous treatment with local corticosteroids within the previous two weeks;
Presence of skin infections or malignancy in the treatment area;
Severe psoriasis;
Patients who require systemically acting medications for the treatment of psoriasis;
Pregnant or breast-feeding females;

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The Psoriasis Area Severity Index (PASI);. Timepoint: PASI score is evaluated at baseline, day 14 and day 28;. Method of measurement: Fotofinder device;.